VIENNA, Austria--(BUSINESS WIRE)--Hemispherx Biopharma, Inc. (AMEX: HEB) announced today that on Friday, October 20, Dr. Hideki Hasegawa, of Japan’s National Institute of Infectious Diseases (JNIID), presented the results of his studies co-administering Hemispherx’s double-stranded RNA (dsRNA) Ampligen® (polyI:polyC12U) experimental therapeutic with an H5N1 vaccine. Dr. Hasegawa’s studies, presented at the Second International Conference on Influenza Vaccines for the World in Vienna, Austria, examined the protective efficacy of intranasal co-administration of inactivated whole-virion H5N1 vaccine with Ampligen® in mice and non-human primates.
